alexa
Reach Us +44-1904-929220
Peptide Phage Display for Discovery of Novel Biomarkers for Imaging and Therapy of Cell Subpopulations in Ovarian Cancer | OMICS International | Abstract
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Peptide Phage Display for Discovery of Novel Biomarkers for Imaging and Therapy of Cell Subpopulations in Ovarian Cancer

Mette Soendergaard1, Jessica R Newton-Northup1, Mark O Palmier1 and Susan L Deutscher1,2*

1University of Missouri, Department of Biochemistry, Columbia, MO 65211

2Harry S Truman Veterans Memorial Hospital, Columbia, MO, 65201

*Corresponding Author:
Susan L Deutscher, Ph.D.
University of Missouri
Department of Biochemistry, Columbia, MO 65211
Tel: 573-882-2454
Fax: 573-884-4597
E-mail: [email protected]

Received date: September 30, 2011; Accepted date: November 15, 2011; Published date: November 19, 2011

Citation: Soendergaard M, Newton-Northup JR, Palmier MO, Deutscher SL (2011) Peptide Phage Display for Discovery of Novel Biomarkers for Imaging and Therapy of Cell Subpopulations in Ovarian Cancer. J Mol Biomark Diagn S2:004. doi:10.4172/2155-9929.S2-004

Copyright: © 2011 Soendergaard M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Ovarian cancer is a very aggressive disease that is mostly asymptomatic at early onset. Approximately 85% of patients are diagnosed at late-stage disease, which greatly compromises full recovery. Standard detection methods include measurement of the ovarian cancer biomarker CA-125. However, CA-125 is associated with false positive diagnosis and is largely limited to late-stage disease. As a result, there is a great need to discover new biomarkers and develop novel detection and imaging methods for ovarian cancer. Patients with ovarian cancer often respond to initial chemotherapy but most will succumb to recurrent disease. Such poor prognosis is associated with a drug resistant subpopulation of cancer cells with stem-like properties known as cancer stem cells (CSC). Traditional chemotherapy fails to target CSC, and it is widely accepted that this process leads to the recurrence of more aggressive tumors. Therefore, it is essential to discover new ovarian CSC biomarkers and develop therapies that specifically target this subpopulation. Bacteriophage (phage) display technology allows identification of high affinity peptides by screening of peptide libraries against cellular targets. The large amount of unique peptides in a library facilitates high throughput selections both in vivo and in vitro. Here we discuss how phage display can be utilized to discover novel peptides with high binding affinity for normal ovarian cancer cells and ovarian CSC. Such peptides may be radiolabeled and employed in SPECT and PET imaging as well as in therapeutic settings. Further, both phage and phage display derived peptides can be employed in identification of targeted antigens and novel ovarian cancer biomarkers using mass spectrometry analysis. Such biomarkers may be utilized in diagnosis and in identification and selection of ovarian cancer subpopulations.

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page
Top